<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00433797</url>
  </required_header>
  <id_info>
    <org_study_id>PFPI</org_study_id>
    <secondary_id>S-06187 (REK Sør)</secondary_id>
    <secondary_id>2006-18 (RRHF)</secondary_id>
    <nct_id>NCT00433797</nct_id>
  </id_info>
  <brief_title>Dietary Intervention With Phytochemicals and Polyunsaturated Fatty Acids in Prostate Cancer Patients</brief_title>
  <official_title>Prostate Phytochemical &amp; PUFA Intervention - a Phase I/II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oslo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Norwegian Cancer Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Research Council of Norway</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Oslo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We will study the effect of dietary intervention in patients with prostate cancer. Outcomes
      include serum PSA kinetics, as well as biomarkers of inflammation, antioxidant status,
      oxidative stress and oxidative damage in blood cells, plasma, urine and prostate tissues
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 102 patients with localized prostate cancer will be included in the study. A the
      time of inclusion, the participants will be randomized to three groups.

      The intervention groups includes; control group, tomato group and multi-diet group. The
      intervention period is three week and will be completed before prostatectomy or radiation
      therapy.

      Biomarkers og inflammation includes: acute phase proteins, cytokines, chemokines and other
      inflammatory mediators. Biomarker of antioxidant status includes vitamin C, vitamin E,
      glutathione, carotenoids, total antioxidant capacity and total phenolics. Oxidative stress
      markers includes; malondialdehyde, isoprostanes, 8-hydroxy-deoxyguanosine, oxidized vitamin
      C, total lipidperoxides (d-ROM) and protein carbonyls.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>serum prostate specific antigen</measure>
    <time_frame>Baseline, after intervention, follow-up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>oxidative stress biomarkers in blood, tissue and urine</measure>
    <time_frame>Baseline, after intervention, follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>antioxidant status biomarkers in blood, tissue and urine</measure>
    <time_frame>Baseline, after intervention, follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>oxidative damage biomarkers in blood, tissue and urine</measure>
    <time_frame>Baseline, after intervention, follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>inflammation biomarkers in blood, tissue and urine</measure>
    <time_frame>Baseline, after intervention, follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apoptose markers in prostate tissue</measure>
    <time_frame>Baseline, after intervention, follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DNA microarrays in blood cells and prostate tissue</measure>
    <time_frame>Baseline, after intervention, follow-up</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">86</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tomato</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multi-diet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Control</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Prostate cancer, phytochemical and PUFA</intervention_name>
    <description>Patients with localized prostate cancer are supplemented with either tomato or a multi-diet cinsisting of grape juice, pomegranate juice, tomato, green tea, black tea, soy, selenium and PUFAs for 3 weeks.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <other_name>PFPI</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adenoarcinoma (as confirmed by histology)

          -  pN0/NXM0 (TNM/UICC 2002) and at least one negative prognosis factor for HDR-BT or low
             risk profile with the use of radical prostatectomy.

          -  Serum PSA&lt; 20 ng/mL, and Gleason score =&gt;6 or T1c- T3a, prostate volume &lt; 60mL

          -  Performance status 0-1

          -  Normal WBC and thromocytes, Hb &gt;11g/dl

        Exclusion Criteria:

          -  No previous endocrine treatment

          -  Life expectancy &gt; 5 år

          -  No possible co-morbidity (CVD, COPD, diabetes type I, vasculatory syndromes or
             inflammatory diseases that may affect quality of life and radiation therapy)

          -  Urinary retention, incontinens or IPPS score &lt;12
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wolfgang Lilleby, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rikshospitalet-Radiumhospitalet, Oslo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sigbjørn Smeland, MD, PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rikshospitalet-Radiumhospitalet, Oslo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oslo Universuty Hospital, Radiumhospitalet and Aker</name>
      <address>
        <city>Oslo</city>
        <zip>0310</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 9, 2007</study_first_submitted>
  <study_first_submitted_qc>February 9, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 12, 2007</study_first_posted>
  <last_update_submitted>December 18, 2013</last_update_submitted>
  <last_update_submitted_qc>December 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 19, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Oslo</investigator_affiliation>
    <investigator_full_name>Rune Blomhoff</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Prostate cancer</keyword>
  <keyword>PSA</keyword>
  <keyword>antioxidant</keyword>
  <keyword>phytochemical</keyword>
  <keyword>tomatoes</keyword>
  <keyword>PUFA</keyword>
  <keyword>selenium</keyword>
  <keyword>soy</keyword>
  <keyword>pomegranate</keyword>
  <keyword>grapes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

